PMID- 34233647 OWN - NLM STAT- MEDLINE DCOM- 20211102 LR - 20211102 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 21 IP - 1 DP - 2021 Jul 7 TI - MCM6 indicates adverse tumor features and poor outcomes and promotes G1/S cell cycle progression in neuroblastoma. PG - 784 LID - 10.1186/s12885-021-08344-z [doi] LID - 784 AB - BACKGROUND: Minichromosome maintenance complex component 6 (MCM6), as an important replication permission factor, is involved in the pathogenesis of various tumors. Here we studied the expression of MCM6 in neuroblastoma and its influence on tumor characteristics and prognosis. METHODS: Publicly available datasets were used to explore the influence of the differential expression of MCM6 on neuroblastoma tumor stage, risk and prognosis. In cell experiments, human neuroblastoma cell lines SK-N-SH and SK-N-BE [ (2)] were utilized to verify the ability of MCM6 to promote cell proliferation, migration and invasion. We further explored the possible molecular mechanism of MCM6 affecting the phenotype of neuroblastoma cells by mutual verification of RNA-seq and western blotting, and flow cytometry to inquire about its potential specific roles in the cell cycle. RESULTS: Through multiple datasets mining, we found that high expression of MCM6 was positively correlated with elevated tumor stage, high risk and poor prognosis in neuroblastoma. At the cellular level, neuroblastoma cell proliferation, migration and invasion were significantly inhibited after MCM6 was interfered by siRNA. Mutual verification of RNA-seq and western blotting suggested that the downstream cell cycle-related genes were differentially expressed after MCM6 interference. Flow cytometric analysis revealed that neuroblastoma cells were blocked in G1/S phase after MCM6 interference. CONCLUSION: MCM6 is considered to be the driving force of G1/S cell cycle progression, and it is also a prognostic marker and a potential novel therapeutic target in neuroblastoma. FAU - Gu, Yaoyao AU - Gu Y AD - Department of Pediatric Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200092, China. AD - Division of Pediatric Oncology, Shanghai Institute of Pediatric Research, Shanghai, 200092, China. FAU - Hu, Xiaoxiao AU - Hu X AD - Department of Pediatric Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200092, China. AD - Division of Pediatric Oncology, Shanghai Institute of Pediatric Research, Shanghai, 200092, China. AD - Department of Pediatric Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China. FAU - Liu, Xiaowei AU - Liu X AD - Department of Pediatric Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200092, China. AD - Division of Pediatric Oncology, Shanghai Institute of Pediatric Research, Shanghai, 200092, China. FAU - Cheng, Cheng AU - Cheng C AD - Department of Pediatric Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200092, China. AD - Division of Pediatric Oncology, Shanghai Institute of Pediatric Research, Shanghai, 200092, China. FAU - Chen, Kai AU - Chen K AD - Department of Pediatric Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200092, China. AD - Division of Pediatric Oncology, Shanghai Institute of Pediatric Research, Shanghai, 200092, China. FAU - Wu, Yeming AU - Wu Y AD - Department of Pediatric Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200092, China. AD - Division of Pediatric Oncology, Shanghai Institute of Pediatric Research, Shanghai, 200092, China. AD - Department of Pediatric Surgery, Children's Hospital of Soochow University, Suzhou, 215003, China. FAU - Wu, Zhixiang AU - Wu Z AUID- ORCID: 0000-0002-3947-2035 AD - Department of Pediatric Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200092, China. wuzhixiang@xinhuamed.com.cn. AD - Division of Pediatric Oncology, Shanghai Institute of Pediatric Research, Shanghai, 200092, China. wuzhixiang@xinhuamed.com.cn. AD - Department of Pediatric Surgery, Children's Hospital of Soochow University, Suzhou, 215003, China. wuzhixiang@xinhuamed.com.cn. LA - eng GR - 81874234/National Natural Science Foundation of China/ GR - SZYJTD201706/Suzhou Clinical Medicine Innovation Team Introduction Project/ GR - 20YF1430300/Shanghai Sailing Program/ PT - Journal Article DEP - 20210707 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Cell Cycle Proteins) RN - EC 3.6.4.12 (MCM6 protein, human) RN - EC 3.6.4.12 (Minichromosome Maintenance Complex Component 6) SB - IM MH - Animals MH - Cell Cycle Proteins/*metabolism MH - Disease Models, Animal MH - Disease Progression MH - Humans MH - Mice MH - Mice, Nude MH - Minichromosome Maintenance Complex Component 6/*adverse effects MH - Neuroblastoma/*genetics/pathology MH - Prognosis MH - Transfection MH - Treatment Outcome PMC - PMC8262023 OTO - NOTNLM OT - Cell cycle OT - MCM6 OT - Neuroblastoma COIS- The authors declare that they have no competing interests. EDAT- 2021/07/09 06:00 MHDA- 2021/11/03 06:00 PMCR- 2021/07/07 CRDT- 2021/07/08 05:37 PHST- 2020/11/05 00:00 [received] PHST- 2021/05/11 00:00 [accepted] PHST- 2021/07/08 05:37 [entrez] PHST- 2021/07/09 06:00 [pubmed] PHST- 2021/11/03 06:00 [medline] PHST- 2021/07/07 00:00 [pmc-release] AID - 10.1186/s12885-021-08344-z [pii] AID - 8344 [pii] AID - 10.1186/s12885-021-08344-z [doi] PST - epublish SO - BMC Cancer. 2021 Jul 7;21(1):784. doi: 10.1186/s12885-021-08344-z.